Center for Substance Abuse Treatment; Notice of Meeting Cancellation, 1181 [2019-00545]

Download as PDF Federal Register / Vol. 84, No. 22 / Friday, February 1, 2019 / Notices Dated: January 28, 2019. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–00640 Filed 1–31–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment; Notice of Meeting Cancellation This is a notice of meeting cancellation of the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Treatment (CSAT) National Advisory Council (NAC) of February 27, 2019, 9:00 a.m.–5:00 p.m. (EDT). The meeting was announced on the Federal Register/Vol. 83, No. 245/ Friday, December 21, 2018/[FR Doc. 2018–27637 Filed 12–20–18]. Future meetings will be announced at a later time. Pertinent council information may be obtained by contacting the CSAT National Advisory Council Designated Federal Officer; Tracy Goss (see contact information below). Council Name: SAMHSA’s Center for Substance Abuse Treatment, National Advisory Council. Contact: Tracy Goss, Designated Federal Officer, CSAT National Advisory Council, 5600 Fishers Lane, Rockville, Maryland 20857 (mail), Telephone: (240) 276–0759, Fax: (240) 276–2252, Email: tracy.goss@ samhsa.hhs.gov. Dated: January 28, 2019. Carlos Castillo, Committee Management Officer. [FR Doc. 2019–00545 Filed 1–31–19; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies Substance Abuse and Mental Health Services Administration, HHS. ACTION: Notice. AGENCY: VerDate Sep<11>2014 21:23 Jan 31, 2019 Jkt 247001 The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). A notice listing all currently HHScertified laboratories and IITFs is published in the Federal Register during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter. This notice is also available on the internet at https://www.samhsa.gov/ workplace. FOR FURTHER INFORMATION CONTACT: Charles LoDico, Division of Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N02C, Rockville, Maryland 20857; 240–276–2600 (voice). SUPPLEMENTARY INFORMATION: The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); April 30, 2010 (75 FR 22809); and on January 23, 2017 (82 FR 7920). The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. The ‘‘Mandatory Guidelines for Federal Workplace Drug Testing Programs,’’ as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies. To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance SUMMARY: PO 00000 Frm 00135 Fmt 4703 Sfmt 4703 1181 testing program plus undergo periodic, on-site inspections. Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards. In accordance with the Mandatory Guidelines dated January 23, 2017 (82 FR 7920), the following HHS-certified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens: HHS-Certified Instrumented Initial Testing Facilities Dynacare, 6628 50th Street NW, Edmonton, AB Canada T6B 2N7, 780– 784–1190, (Formerly: GammaDynacare Medical Laboratories) HHS-Certified Laboratories ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 844–486–9226 Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504–361–8989/ 800–433–3823, (Formerly: Kroll Laboratory Specialists, Inc., Laboratory Specialists, Inc.) Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236, 804–378–9130, (Formerly: Kroll Laboratory Specialists, Inc., Scientific Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.) Baptist Medical Center—Toxicology Laboratory, 11401 I–30, Little Rock, AR 72209–7056, 501–202–2783, (Formerly: Forensic Toxicology Laboratory Baptist Medical Center) Clinical Reference Laboratory, Inc., 8433 Quivira Road, Lenexa, KS 66215– 2802, 800–445–6917 Cordant Health Solutions, 2617 East L Street, Tacoma, WA 98421, 800–442– 0438, (Formerly: STERLING Reference Laboratories) DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800– 235–4890 Dynacare*, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519– 679–1630, (Formerly: GammaDynacare Medical Laboratories) ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 662– 236–2609 Laboratory Corporation of America Holdings, 7207 N Gessner Road, Houston, TX 77040, 713–856–8288/ 800–800–2387 Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ E:\FR\FM\01FEN1.SGM 01FEN1

Agencies

[Federal Register Volume 84, Number 22 (Friday, February 1, 2019)]
[Notices]
[Page 1181]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-00545]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Center for Substance Abuse Treatment; Notice of Meeting 
Cancellation

    This is a notice of meeting cancellation of the Substance Abuse and 
Mental Health Services Administration's (SAMHSA) Center for Substance 
Abuse Treatment (CSAT) National Advisory Council (NAC) of February 27, 
2019, 9:00 a.m.-5:00 p.m. (EDT). The meeting was announced on the 
Federal Register/Vol. 83, No. 245/Friday, December 21, 2018/[FR Doc. 
2018-27637 Filed 12-20-18].
    Future meetings will be announced at a later time. Pertinent 
council information may be obtained by contacting the CSAT National 
Advisory Council Designated Federal Officer; Tracy Goss (see contact 
information below).
    Council Name: SAMHSA's Center for Substance Abuse Treatment, 
National Advisory Council.
    Contact: Tracy Goss, Designated Federal Officer, CSAT National 
Advisory Council, 5600 Fishers Lane, Rockville, Maryland 20857 (mail), 
Telephone: (240) 276-0759, Fax: (240) 276-2252, Email: 
tracy.goss@samhsa.hhs.gov.

    Dated: January 28, 2019.
Carlos Castillo,
Committee Management Officer.
[FR Doc. 2019-00545 Filed 1-31-19; 8:45 am]
BILLING CODE 4162-20-P